Exercise of Options

Oxford Pharmascience Group plc

 ("Oxford Pharmascience" or "the Company")

Exercise of share options

Oxford Pharmascience Group plc announces that it has issued 8,125,000 ordinary shares of 0.1 pence each ("Ordinary Shares") in the Company following the exercise of 8,125,000 options under the Company's approved share option plan, by Nigel Theobald, a former director of the Company.

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 17 April 2014.

Immediately following Admission, the Company will have 1,005,661,619 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 1,005,661,619 and this figure may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive +44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell/Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. 

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.